Caspian Therapeutics, Inc.

BiotechnologyBiotechnologyDiabetesSpin-out

📍 San Diego, CA, United States

StreetZero Signal 80

Be the first to signal interest

About Caspian Therapeutics, Inc.

Caspian Therapeutics, Inc. was spun out from Kura Oncology to advance an investigational menin inhibitor for diabetes. The lead asset KO-7246 aims to increase the number and activity of beta cells in the pancreas to boost insulin production. The company received $50 million in funding to support initial clinical proof-of-concept assessments, IND-enabling development, and a second menin blocker for diabetes and cardiometabolic conditions, with support from Lilly.

LATEST FUNDINGPrivate Placement

$50.0M

Announced 2026-09-23

TOTAL RAISED$50,000,000

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Caspian Therapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQSan Diego, CA, United States

Industry

Biotechnology

Investors

Eli Lilly

Key highlights

Spun out from Kura Oncology specifically for diabetes programs.
$50M private placement supports clinical PoC and IND-enabling work on KO-7246.
Focuses on menin inhibition to expand pancreatic beta cells and improve insulin production.
Lilly provided support for the diabetes and cardiometabolic pipeline.

Ask StreetZero about Caspian Therapeutics, Inc.

Put our AI to work on this deal.

What is Caspian Therapeutics, Inc.'s value proposition?Who are Caspian Therapeutics, Inc.'s competitors?Why does this raise matter?Summarize Caspian Therapeutics, Inc. for an investor.

Similar companies

Other Biotechnology deals, ranked by Signal.

Pictura Bio US, Inc.

$15.0M

Typewriter Therapeutics, Inc.

$56.3M

BioStem Technologies, Inc.

$40.0M

Xact Bio, Inc.

$10.0M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.